Milestone Pharmaceuticals Inc. (MIST) company profile
Close on Nov 13, 2026Market cap $64.74MP/E –Yield –
About Milestone Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel cardiovascular medicines. Its lead commercial product is CARDAMYST (etripamil) nasal spray, a self-administered, rapid-onset calcium channel blocker designed to convert acute symptomatic attacks of paroxysmal supraventricular tachycardia (PSVT) into normal sinus rhythm. In addition to commercializing CARDAMYST, the company develops etripamil to manage acute ventricular rates in patients suffering from atrial fibrillation with rapid ventricular rate (AFib-RVR). Its target customers comprise healthcare providers—predominantly clinical cardiologists, interventional cardiologists, electrophysiologists, and select primary care physicians—who treat adult patients with these episodic cardiac arrhythmias, with products supplied via third-party logistics to drug wholesalers and retail pharmacies.
The company markets its treatment in the United States using a dedicated specialty sales team of roughly 60 representatives who call on thousands of prescribers. Internationally, the company pursues commercialization and regulatory approvals through regional partnerships, including marketing authorization applications submitted in the European Union and China. Milestone Pharmaceuticals operates without internal manufacturing facilities, relying entirely on a global contract supply chain for drug substance production, device formulation, assembly, and packaging. The provided excerpt does not disclose the location of the company's headquarters.
Summary of the business section of Milestone Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Milestone Pharmaceuticals Inc.
- Headquarters
- Montreal, A8
- Address
- 1111 Boul. Dr.-Frederik-Philips, Ste 420 H4M 2X6
- Phone
- (514) 336-0444
- Website
- milestonepharma.com
- Employees
- 38, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A8
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Montreal, Canada
Stock & identifiers
- Ticker
- MIST
- Exchange
- Nasdaq
- IPO date
- May 9, 2019
- Shares outstanding
- 124M, Aug 12, 2026
- Public float
- $98.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1408443
- CUSIP
- 59935V107
- ISIN
- CA59935V1076
- FIGI
- BBG009DR4MN8
- Share class FIGI
- BBG009DR4MP6
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joseph Oliveto | President and CEO, Director | 446,244 |
| David I. Sandoval | GC & Chief Compliance Officer | – |
| Amit Hasija | CFO & EVP of Corp. Development | 112,093 |
| Lorenz Muller | Chief Commercial Officer | 205,406 |
| David Bharucha | Chief Medical Officer | 125,426 |
| Jeffrey Edward Nelson | Chief Operating Officer | 49,848 |
| Stuart Duty | Director | – |
| Robert James Wills | Director | 65,000 |
| Joseph C. Papa | Director | 100,000 |
| Seth H. Z. Fischer | Director | – |
| Michael John Tomsicek | Director | 15,000 |
| Andrew Saik | Director | – |
| Lisa M. Giles | Director | – |
| Debra K. Liebert | Director | 30,793 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $2.12M | $2.86M | $1.01M | $86 | – |
| FY2024 | $854.27K | $945.16K | $590.84K | $141 | – |
| FY2023 | $1.98M | $454.21K | $1.11M | $42 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Joseph Oliveto Chief Executive Officer & President | $649.64K | $538.13K | $651.49K | $250.11K | $31.63K | $2.12M | +148% |
| David Bharucha Chief Medical Officer | $504.19K | $162.41K | $197.64K | $141.17K | $19.06K | $1.02M | +68% |
| Amit Hasija Chief Financial Officer and Executive Vice President of Corporate Development | $472.77K | $162.41K | $197.64K | $132.38K | $26.71K | $991.91K | +73% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 9, 2019
- Offer price
- $15.00
- Exchange
- Nasdaq
- First trading day
- May 9, 2019
- First-day close
- $15.37+2.5%
- Lock-up ends (est.)
- Nov 5, 2019
“The initial public offering price is $15.00 per common share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 38 full-time employees, 13 of whom were primarily engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 28, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 9, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| May 6, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?